"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2023/192570 A1,041-560-530-927-050,2023-10-05,2023,US 2023/0017052 W,2023-03-31,US 202263326701 P,2022-04-01,RATIO OF RED TO FAR-RED LIGHT SUPPLEMENTATION TO ENHANCE PLANT GROWTH IN CONTROLLED ENVIRONMENTS,"The present invention is directed at a method to enhance the growth of a plant in a controlled growing environment by using light sources which illuminate the plant. The method involves selecting a first frequency and first intensity for the light source, then selecting a second frequency and a second intensity for the light source, and maintaining the first and second intensities at a predetermined ratio. The first frequency may be selected from the range of approximately 620 to approximately 700 nanometers and the second may be selected from the range of approximately 700 to approximately 750 nanometers. The predetermined ratio may be between 1.73 – 2.60 and most preferably 1.74.",BENSON HILL INC,NEWMAN LISA;;FISCHER EDWARD;;DUNCAN LOGAN;;RHANOR THOMAS,,https://lens.org/041-560-530-927-050,Patent Application,yes,5,0,1,1,0,A01G7/045,A01G9/24,,0,0,,,,PENDING
2,EP,A2,EP 1751146 A2,185-796-664-427-900,2007-02-14,2007,EP 05702134 A,2005-02-07,GB 2005000405 W;;GB 0402653 A,2004-02-06,PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD,DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/185-796-664-427-900,Patent Application,yes,0,0,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/00;;C07D417/04;;C07D417/14,,0,0,,,,ACTIVE
3,DE,D1,DE 602005018044 D1,047-621-646-309-136,2010-01-14,2010,DE 602005018044 T,2005-02-07,GB 0402653 A;;GB 2005000405 W,2004-02-06,PYRIDINYL- ODER PYRIMIDINYLTHIAZOLE MIT PROTEINKINASEHEMMENDER WIRKUNG,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD,DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/047-621-646-309-136,Granted Patent,no,0,0,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/00;;C07D417/04;;C07D417/14,,0,0,,,,INACTIVE
4,EP,B1,EP 1751146 B1,189-787-000-908-059,2009-12-02,2009,EP 05702134 A,2005-02-07,GB 2005000405 W;;GB 0402653 A,2004-02-06,PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD,DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/189-787-000-908-059,Granted Patent,yes,5,0,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/00;;C07D417/04;;C07D417/14,,1,0,,,"ZIMMERMANN J ET AL: ""PHENYLAMINO-PYRIMIDINE (PAP) DERIVATIVES: A NEW CLASS OF POTENT ANDSELECTIVE INHIBITORS OF PROTEIN KINASE C (PKC)"" July 1996 (1996-07), ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, PAGE(S) 371-376 , XP000885618 ISSN: 0365-6233 page 372 - page 373; tables I,II",ACTIVE
5,WO,A3,WO 2005/075468 A3,066-769-477-086-276,2005-10-13,2005,GB 2005000405 W,2005-02-07,GB 0402653 A,2004-02-06,PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1:1 is N or CH; ;Z2 and Z3 are each independently N or CR7; :Rl, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14 (CH2)aCOOR15, (CH2)bCONR16R17, (CH2)C COR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when Rl and R2 are both H, Zl is CH; or Z2 is N; or Zl is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5&shy;trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)&shy;N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD;;DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA;;FISCHER PETER,DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/066-769-477-086-276,Search Report,yes,5,0,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;C07D417/14,,1,1,076-446-044-984-990,10.1002/ardp.19963290707;;8764886,"ZIMMERMANN J ET AL: ""PHENYLAMINO-PYRIMIDINE (PAP) DERIVATIVES: A NEW CLASS OF POTENT ANDSELECTIVE INHIBITORS OF PROTEIN KINASE C (PKC)"", July 1996, ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, PAGE(S) 371-376, ISSN: 0365-6233, XP000885618",PENDING
6,AU,A1,AU 2005/210254 A1,034-318-266-085-421,2005-08-18,2005,AU 2005/210254 A,2005-02-07,GB 0402653 A;;GB 2005000405 W,2004-02-06,Pyridinyl - or pyrimidinyl thiazoles with protein kinase inhibiting activity,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD,GIBSON DARREN;;ZHELEVA DANIELLA;;DUNCAN KENNETH;;WANG SHUDONG;;FISCHER PETER,,https://lens.org/034-318-266-085-421,Patent Application,no,0,0,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;C07D417/14,,0,0,,,,DISCONTINUED
7,CA,A1,CA 2554329 A1,075-928-385-015-181,2005-08-18,2005,CA 2554329 A,2005-02-07,GB 0402653 A;;GB 2005000405 W,2004-02-06,PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1:1 is N or CH; ;Z2 and Z3 are each independently N or CR7; :Rl, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; an d each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R1 2, NR13R14 (CH2)aCOOR15, (CH2)bCONR16R17, (CH2)CCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when Rl and R2 are both H, Zl is CH; or Z2 is N; or Zl is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazo l- 2-yl)-N-(3,4,5~trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)- 4- methylthiazol-2-yl)~N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.</S DOAB>",CYCLACEL LTD,FISCHER PETER;;WANG SHUDONG;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;GIBSON DARREN,,https://lens.org/075-928-385-015-181,Patent Application,no,0,0,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;A61K31/506;;C07D417/14,,0,0,,,,DISCONTINUED
8,AT,T1,AT E450532 T1,195-491-695-391-66X,2009-12-15,2009,AT 05702134 T,2005-02-07,GB 0402653 A;;GB 2005000405 W,2004-02-06,PYRIDINYL- ODER PYRIMIDINYLTHIAZOLE MIT PROTEINKINASEHEMMENDER WIRKUNG,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD,DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/195-491-695-391-66X,Granted Patent,no,0,0,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;C07D417/14,,0,0,,,,INACTIVE
9,WO,A2,WO 2005/075468 A2,172-477-269-790-793,2005-08-18,2005,GB 2005000405 W,2005-02-07,GB 0402653 A,2004-02-06,PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1:1 is N or CH; ;Z2 and Z3 are each independently N or CR7; :Rl, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14 (CH2)aCOOR15, (CH2)bCONR16R17, (CH2)C COR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when Rl and R2 are both H, Zl is CH; or Z2 is N; or Zl is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5&shy;trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)&shy;N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD;;DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA;;FISCHER PETER,DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/172-477-269-790-793,Patent Application,yes,0,42,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;C07D417/14,,0,0,,,,PENDING
10,BR,A,BR 0316703 A,185-401-725-629-268,2005-10-18,2005,BR 0316703 A,2003-12-18,GB 0229581 A;;GB 0305558 W,2002-12-19,Aplicações terapêuticas de 4-hetero-arilpirimidinas 2-substituìdas,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f"" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f"" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHEVELA DANIELLA;;FISCHER PETER,,https://lens.org/185-401-725-629-268,Patent Application,no,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,DISCONTINUED
11,AT,T1,AT E386529 T1,179-895-285-176-984,2008-03-15,2008,AT 03768023 T,2003-12-18,GB 0229581 A,2002-12-19,PHARMAZEUTISCHE VERWENDUNGEN VON 2-SUBSTITUIERTEN 4-HETEROARYLPYRIMIDINEN,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f"" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f"" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/179-895-285-176-984,Granted Patent,no,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,EXPIRED
12,NZ,A,NZ 539671 A,152-285-612-035-735,2007-04-27,2007,NZ 53967103 A,2003-12-18,GB 0229581 A;;GB 0305558 W,2002-12-19,"2-substituted 4-heteroarylpyrimidines suitable for treating diabetes, CNS disorders, alopecia, cardiovascular disorders and stroke","The disclosure relates to the use of 2-substituted 4-heteroarylpyrimidine compounds of formula (I), or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating diabetes, wherein the variables shown in formula (I) are as defined in the specification. These compounds of formula (I) also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHEVELA DANIELLA;;FISCHER PETER,,https://lens.org/152-285-612-035-735,Patent Application,no,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,PENDING
13,DE,D1,DE 60319269 D1,047-647-864-977-242,2008-04-03,2008,DE 60319269 T,2003-12-18,GB 0229581 A;;GB 0305558 W,2002-12-19,PHARMAZEUTISCHE VERWENDUNGEN VON 2-SUBSTITUIERTEN 4-HETEROARYLPYRIMIDINEN,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f"" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f"" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/047-647-864-977-242,Granted Patent,no,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,EXPIRED
14,EP,A1,EP 1572211 A1,043-798-912-611-919,2005-09-14,2005,EP 03768023 A,2003-12-18,GB 0305558 W;;GB 0229581 A,2002-12-19,THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f"" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f"" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;FISCHER PETER,CYCLACEL LIMITED (2007-07-11),https://lens.org/043-798-912-611-919,Patent Application,yes,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,EXPIRED
15,EP,B1,EP 1572211 B1,037-367-081-114-150,2008-02-20,2008,EP 03768023 A,2003-12-18,GB 0305558 W;;GB 0229581 A,2002-12-19,THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f"" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f"" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;FISCHER PETER,CYCLACEL LIMITED (2007-07-11),https://lens.org/037-367-081-114-150,Granted Patent,yes,7,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,EXPIRED
16,BR,A,BR PI0507506 A,170-128-712-536-733,2007-06-26,2007,BR PI0507506 A,2005-02-07,GB 0402653 A;;GB 2005000405 W,2004-02-06,compostos,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z1: 1 is N or CH; Z2 and Z3 are each independently N or CR7; R1, R2, R3, R4, R5, R6, and R7 are each independently H, R8, or R9; each R8 is independently a hydrocarbyl group; and each R9 is independently halo, NO2, alkoxy, CN, CF3, S03H, SO2NR10R11, S02R12, NR13R14(CH2)aCOOR15, (CH2)bCONR16R17, (CH2)cCOR18 or (CH2)dOH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R1 and R2 are both H, Z1 is CH; or Z2 is N; or Z1 is CH and Z2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD,DUNCAN KENNETH W;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA I;;FISCHER PETER,,https://lens.org/170-128-712-536-733,Patent Application,no,0,0,14,14,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;A61K31/506;;C07D417/14,,0,0,,,,DISCONTINUED
17,DE,T2,DE 60319269 T2,098-643-271-855-444,2009-02-26,2009,DE 60319269 T,2003-12-18,GB 0229581 A;;GB 0305558 W,2002-12-19,PHARMAZEUTISCHE VERWENDUNGEN VON 2-SUBSTITUIERTEN 4-HETEROARYLPYRIMIDINEN,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f"" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f"" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/098-643-271-855-444,Granted Patent,no,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,EXPIRED
18,AU,A1,AU 2003/292444 A1,177-371-778-247-031,2004-07-14,2004,AU 2003/292444 A,2003-12-18,GB 0229581 A;;GB 0305558 W,2002-12-19,THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f"" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f"" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,DUNCAN KENNETH;;ZHEVELA DANIELLA;;FISCHER PETER;;WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN,,https://lens.org/177-371-778-247-031,Patent Application,no,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,DISCONTINUED
19,US,A1,US 2008/0318954 A1,112-705-547-884-104,2008-12-25,2008,US 58837205 A,2005-02-07,GB 0402653 A;;GB 2005000405 W,2004-02-06,Compounds,"The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z 1 : 1 is N or CH; Z 2 and Z 3 are each independently N or CR 7 ; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are each independently H, R 8 , or R 9 ; each R 8 is independently a hydrocarbyl group; and each R 9 is independently halo, NO 2 , alkoxy, CN, CF 3 , S0 3 H, SO 2 NR 10 R 11 , S0 2 R 12 , NR 13 R 14 (CH 2 ) a COOR 15 , (CH 2 ) b CONR 16 R 17 , (CH 2 ) c COR 18 or (CH 2 ) d OH; a, b, c and d are each independently 0, 1 2 3 or 4; R10-18 are each independently H or alkyl; provided that when R 1 and R 2 are both H, Z 1 is CH; or Z 2 is N; or Z 1 is CH and Z 2 is N; and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine. Further aspects relate to the use of compounds of formula (I) in the preparation of a medicament for treating one or more disorders selected from a proliferative disorder, a viral disorder, a CNS disorder, diabetes, stroke or alopecia.",CYCLACEL LTD,DUNCAN KENNETH;;GIBSON DARREN;;WANG SHUDONG;;ZHELEVA DANIELLA I;;FISCHER PETER MARTIN,CYCLACEL LIMITED (2006-12-13),https://lens.org/112-705-547-884-104,Patent Application,yes,22,3,14,14,2,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/08;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D417/04;;C07D417/14,A61K31/505;;A61K31/444;;A61K31/5355;;A61P19/08;;C07D401/02;;C07D413/02;;C07D417/04;;C07D417/14,514/235.8;;544/331;;514/275;;544/122;;546/270.4;;514/342;;435/15,0,0,,,,DISCONTINUED
20,WO,A1,WO 2004/056368 A1,105-260-259-630-019,2004-07-08,2004,GB 0305558 W,2003-12-18,GB 0229581 A,2002-12-19,THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES,"The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R5, and the other is C-R6; 'a' is a single bond; 'b', 'c', 'd', 'e' and 'f&apos; are single or double bonds so as to form a heteroaryl ring; R1 is is R7 with the proviso that R1 is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R5; 'a' and 'd' are each double bonds; 'b', 'c', 'e' and 'f&apos; are each single bonds; R1 is oxo; and R2, R3, R4, R5, and R6 are each independently H or R7; R7 is a group (CH2)n-R8, wherein n is 0, 1, 2, 3 or 4 and wherein R8 is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF3, NO2, CN, OH, O-alkyl, O-aryl, 0&shy;- heteroaryl, 0-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH2, NH-alkyl, NH-aryl, N(alkyl)2, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH2, CONH-alkyl, CON(alkyl)2, CONH-aryl, CONH-heteroaryl, CONH&shy;heterocycloalkyl, SO3H, S02-alkyl, SO2-aryl, S02-heteroaryl, SO2-heterocycloalkyl, SO2NH2, SO2NH-alkyl, SO2N(alkyl)2, SO2NH-aryl, SO2NH-heteroaryl, or SO2NH&shy;heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO2, OH, 0&shy;methyl, NH2, COOH, CONH2 and CF3; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD;;WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHEVELA DANIELLA;;FISCHER PETER,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHEVELA DANIELLA;;FISCHER PETER,,https://lens.org/105-260-259-630-019,Patent Application,yes,7,29,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,PATENTED
21,CA,A1,CA 2502138 A1,151-575-085-250-386,2004-07-08,2004,CA 2502138 A,2003-12-18,GB 0229581 A;;GB 0305558 W,2002-12-19,THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES,"The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, a nd the other is N; or one of X and Y is NH or N-R5, and the other is C-R6; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f' are single or double bonds so as t o form a heteroaryl ring; R1 is is R7 with the proviso that R1 is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R5; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f' are each single bonds; R1 is ox o; and R2, R3, R4, R5, and R6 are each independently H or R7; R7 is a group (CH2)n-R8, wherein n is 0, 1, 2, 3 or 4 and wherein R8is selected from alkyl , aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF3, NO2, CN, OH, O-alkyl, O- aryl, 0~- heteroaryl, 0-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO- heterocycloalkyl, COO-alkyl, NH2, NH-alkyl, NH-aryl, N(alkyl)2, NH-heteroary l, NH-heterocycloalkyl, COOH, CONH2, CONH-alkyl, CON(alkyl)2, CONH-aryl, CONH- heteroaryl, CONH~heterocycloalkyl, SO3H, S02-alkyl, SO2-aryl, S02-heteroaryl , SO2-heterocycloalkyl, SO2NH2, SO2NH-alkyl, SO2N(alkyl)2, SO2NH-aryl, SO2NH- heteroaryl, or SO2NH~heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more grou ps selected from halogeno, NO2, OH, 0~methyl, NH2, COOH, CONH2 and CF3; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia , cardiovascular disorders and stroke.",CYCLACEL LTD,WOOD GAVIN;;ZHEVELA DANIELLA;;MEADES CHRISTOPHER;;DUNCAN KENNETH;;WANG SHUDONG;;FISCHER PETER,,https://lens.org/151-575-085-250-386,Patent Application,no,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,DISCONTINUED
22,ES,T3,ES 2300617 T3,125-149-099-726-061,2008-06-16,2008,ES 03768023 T,2003-12-18,GB 0229581 A,2002-12-19,APLICACIONES TERAPEUTICAS DE 4-HETEROARILPIRIMIDINAS 2-SUSTITUIDAS.,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N-R<SUP>5</SUP>, and the other is C-R<SUP>6</SUP>; ""a"" is a single bond; ""b"", ""c"", ""d"", ""e"" and ""f"" are single or double bonds so as to form a heteroaryl ring; R<SUP>1 </SUP>is is R<SUP>7 </SUP>with the proviso that R<SUP>1 </SUP>is other than H or Me; or (B) one of X and Y is S, and the other is NH or N-R<SUP>5</SUP>; ""a"" and ""d"" are each double bonds; ""b"", ""c"", ""e"" and ""f"" are each single bonds; R<SUP>1 </SUP>is oxo; and R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, and R<SUP>6 </SUP>are each independently H or R<SUP>7</SUP>; R<SUP>7 </SUP>is a group (CH<SUB>2</SUB>)<SUB>n</SUB>-R<SUP>8</SUP>, wherein n is 0, 1, 2, 3 or 4 and wherein R<SUP>8 </SUP>is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF<SUB>3</SUB>, NO<SUB>2</SUB>, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH<SUB>2</SUB>, NH-alkyl, NH-aryl, N(alkyl)<SUB>2</SUB>, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH<SUB>2</SUB>, CONH-alkyl, CON(alkyl)<SUB>2</SUB>, CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO<SUB>3</SUB>H, SO<SUB>2</SUB>-alkyl, SO<SUB>2</SUB>-aryl, SO<SUB>2</SUB>-heteroaryl, SO<SUB>2</SUB>-heterocycloalkyl, SO<SUB>2</SUB>NH<SUB>2</SUB>, SO<SUB>2</SUB>NH-alkyl, SO<SUB>2</SUB>N(alkyl)<SUB>2</SUB>, SO<SUB>2</SUB>NH-aryl, SO<SUB>2</SUB>NH-heteroaryl, or SO<SUB>2</SUB>NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO<SUB>2</SUB>, OH, O-methyl, NH<SUB>2</SUB>, COOH, CONH<SUB>2 </SUB>and CF<SUB>3</SUB>; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;FISCHER PETER,,https://lens.org/125-149-099-726-061,Granted Patent,no,0,0,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,,0,0,,,,EXPIRED
23,WO,A2,WO 2005/116025 A2,166-106-694-717-474,2005-12-08,2005,GB 2005002134 W,2005-05-26,GB 0411791 A,2004-05-26,2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS,"The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.",CYCLACEL LTD;;WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARRON;;MCLACHLAN JANICE;;FISCHER PETER,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARRON;;MCLACHLAN JANICE;;FISCHER PETER,,https://lens.org/166-106-694-717-474,Patent Application,yes,0,40,13,13,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P11/08;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/00;;C07D417/04;;C07D417/14,,0,0,,,,PENDING
24,MX,A,MX PA06013632 A,165-171-749-096-068,2007-03-23,2007,MX PA06013632 A,2005-05-26,GB 0411791 A;;GB 2005002134 W,2004-05-26,COMPOUNDS.,"The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.",CYCLACEL LTD,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;FISCHER PETER;;DUNCAN KENNETH;;GIBSON DARRON;;MCLACHLAN JANICE,,https://lens.org/165-171-749-096-068,Patent Application,no,0,0,13,13,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P11/08;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,A61K31/00;;C07D417/00;;C07D417/04;;C07D417/14,,0,0,,,,DISCONTINUED
25,CA,A1,CA 2566051 A1,114-313-129-669-102,2005-12-08,2005,CA 2566051 A,2005-05-26,GB 0411791 A;;GB 2005002134 W,2004-05-26,2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS,,CYCLACEL LTD,MEADES CHRISTOPHER;;GIBSON DARRON;;FISCHER PETER;;MCLACHLAN JANICE;;WANG SHUDONG;;DUNCAN KENNETH;;WOOD GAVIN,,https://lens.org/114-313-129-669-102,Patent Application,no,0,0,13,13,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P11/08;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;A61K31/505;;C07D417/00;;C07D417/14,,0,0,,,,DISCONTINUED
26,AU,A1,AU 2005/247682 A1,130-616-585-639-829,2005-12-08,2005,AU 2005/247682 A,2005-05-26,GB 0411791 A;;GB 2005002134 W,2004-05-26,2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders,,CYCLACEL LTD,WOOD GAVIN;;FISCHER PETER;;WANG SHUDONG;;GIBSON DARRON;;MCLACHLAN JANICE;;MEADES CHRISTOPHER;;DUNCAN KENNETH,,https://lens.org/130-616-585-639-829,Patent Application,no,0,0,13,13,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P11/08;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;A61K31/505;;C07D417/00;;C07D417/14,,0,0,,,,DISCONTINUED
27,WO,A3,WO 2005/116025 A3,089-148-332-170-509,2006-02-23,2006,GB 2005002134 W,2005-05-26,GB 0411791 A,2004-05-26,2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS,"The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.",CYCLACEL LTD;;WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARRON;;MCLACHLAN JANICE;;FISCHER PETER,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARRON;;MCLACHLAN JANICE;;FISCHER PETER,,https://lens.org/089-148-332-170-509,Search Report,yes,2,0,13,13,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P11/08;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/00;;C07D417/04;;C07D417/14,,0,0,,,,PENDING
28,EP,A2,EP 1756098 A2,173-002-724-700-313,2007-02-28,2007,EP 05748147 A,2005-05-26,GB 2005002134 W;;GB 0411791 A,2004-05-26,2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS,,CYCLACEL LTD,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARRON;;MCLACHLAN JANICE;;FISCHER PETER,CYCLACEL LIMITED (2013-08-14),https://lens.org/173-002-724-700-313,Patent Application,yes,0,0,13,13,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P11/08;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;C07D417/00;;C07D417/14,,0,0,,,,DISCONTINUED
29,US,A1,US 2005/0282843 A1,121-656-904-184-738,2005-12-22,2005,US 14013605 A,2005-05-26,GB 0229581 A;;GB 0305558 W,2002-12-19,Therapeutic applications of 2-substituted 4-heteroarylpyrimidines,"The present invention relates to the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein (A) one of X and Y is S, and the other is N; or one of X and Y is NH or N—R 5 , and the other is C—R 6 ; “a” is a single bond; “b”, “c”, “d”, “e” and “f” are single or double bonds so as to form a heteroaryl ring; R 1 is is R 7 with the proviso that R 1 is other than H or Me; or(B) one of X and Y is S, and the other is NH or N—R 5 ; “a” and “d” are each double bonds; “b”, “c”, “e” and “f” are each single bonds; R 1 is oxo; andR 2 , R 3 , R 4 , R 5 , and R 6 are each independently H or R 7 ;R 7 is a group (CH 2 ) n —R 8 , wherein n is 0, 1, 2, 3 or 4 and wherein R 8 is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF 3 , NO 2 , CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH 2 , NH-alkyl, NH-aryl, N(alkyl) 2 , NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH 2 , CONH-alkyl, CON(alkyl) 2 , CONH-aryl, CONH-heteroaryl, CONH-heterocycloalkyl, SO 3 H, SO 2 -alkyl, SO 2 -aryl, SO 2 -heteroaryl, SO 2 -heterocycloalkyl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 N(alkyl) 2 , SO 2 NH-aryl, SO 2 NH-heteroaryl, or SO 2 NH-heterocycloalkyl, wherein said alkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted with one or more groups selected from halogeno, NO 2 , OH, O-methyl, NH 2 , COOH, CONH 2 and CF 3 ; in the preparation of a medicament for treating diabetes. The compounds of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke.",WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHELEVA DANIELLA I;;FISCHER PETER M,WANG SHUDONG;;MEADES CHRISTOPHER;;WOOD GAVIN;;DUNCAN KENNETH;;ZHELEVA DANIELLA I;;FISCHER PETER M,CYCLACEL LIMITED (2005-08-04),https://lens.org/121-656-904-184-738,Patent Application,yes,17,30,17,17,0,A61K31/506;;A61P17/14;;A61P25/00;;A61P25/28;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/10;;A61P3/10;;A61K31/506,A61K31/506;;A61P5/48;;A61P9/00;;A61P17/14;;A61P25/00,514/275,0,0,,,,DISCONTINUED
30,BR,A,BR PI0511616 A,150-135-277-287-508,2008-01-02,2008,BR PI0511616 A,2005-05-26,GB 0411791 A;;GB 2005002134 W,2004-05-26,compostos,"COMPOSTOS. A presente invenção refere-se a pirimidinas substituídas selecionadas, sua preparação, composições farmacêuticas contendo as mesmas e seu uso como inibidores de uma ou mais cinases protéicas, e por conseguinte seu uso no tratamento de distúrbios proliferativos, distúrbios virais e/ou outros distúrbios.",CYCLACEL LTD,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARRON;;MCLACHLAN JANICE;;FISCHER PETER,,https://lens.org/150-135-277-287-508,Patent Application,no,0,0,13,13,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P11/08;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/04;;A61K31/505;;C07D417/00;;C07D417/14,,0,0,,,,DISCONTINUED
31,US,A1,US 2009/0137572 A1,013-920-720-491-033,2009-05-28,2009,US 59674005 A,2005-05-26,GB 0411791 A;;GB 2005002134 W,2004-05-26,2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders,"The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.",WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE;;FISCHER PETER MARTIN,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE;;FISCHER PETER MARTIN,CYCLACEL LIMITED (2008-09-15),https://lens.org/013-920-720-491-033,Patent Application,yes,25,11,13,13,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P11/08;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,A61K31/541;;A61K31/5377;;A61P35/00;;C07D417/00;;C07D417/04;;C07D417/14;;C12N9/99;;C12Q1/48;;G01N33/53,514/227.8;;544/122;;514/235.8;;544/60;;435/184;;435/15;;435/7.8,2,0,,,Pinedo et al;;McMahon et al,DISCONTINUED
32,US,A1,US 2009/0318446 A1,155-716-219-298-986,2009-12-24,2009,US 79444906 A,2006-01-11,GB 0500492 A;;GB 2006000087 W,2005-01-11,4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy,"The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof. The present invention seeks to provide further substituted heteroaryl-substituted pyrimidine derivatives. More specifically, the invention relates to compounds that have broad therapeutic applications in the treatment of a number of different diseases and/or that are capable of inhibiting one or more protein kinases.",CYCLACEL LTD,FISCHER PETER MARTIN;;WANG SHUDONG;;MEADES CHRISTOPHER;;ANDREWS MATIN J I;;GIBSON DARREN;;DUNCAN KENNETH,CYCLACEL LIMITED (2007-10-04),https://lens.org/155-716-219-298-986,Patent Application,yes,0,33,11,11,0,C07D401/14;;C07D403/04;;C07D405/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;C07D401/14;;C07D405/14;;C07D403/04,A61K31/506;;A61K31/5377;;A61P11/00;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D413/14;;G01N33/53,514/235.2;;544/331;;544/122;;544/295;;514/275;;514/252.19;;435/7.93,0,0,,,,DISCONTINUED
33,AU,A1,AU 2006/205710 A1,195-292-267-121-653,2006-07-20,2006,AU 2006/205710 A,2006-01-11,GB 0500492 A;;GB 2006000087 W,2005-01-11,4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy,,CYCLACEL LTD,MEADES CHRISTOPHER KEITH;;DUNCAN KENNETH;;WANG SHUDONG;;FISCHER PETER MARTIN;;ANDREWS MARTIN JAMES INGLIS;;GIBSON DARREN,,https://lens.org/195-292-267-121-653,Patent Application,no,0,0,11,11,0,C07D401/14;;C07D403/04;;C07D405/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;C07D401/14;;C07D405/14;;C07D403/04,C07D401/14;;A61K31/506;;A61K31/5377;;A61P5/48;;A61P9/00;;A61P9/04;;A61P17/14;;A61P25/00;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;C07D403/04;;C07D405/14,,0,0,,,,DISCONTINUED
34,CA,A1,CA 2592723 A1,004-857-479-251-694,2006-07-20,2006,CA 2592723 A,2006-01-11,GB 0500492 A;;GB 2006000087 W,2005-01-11,4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY,,CYCLACEL LTD,MEADES CHRISTOPHER KEITH;;WANG SHUDONG;;GIBSON DARREN;;ANDREWS MARTIN JAMES INGLIS;;DUNCAN KENNETH;;FISCHER PETER MARTIN,,https://lens.org/004-857-479-251-694,Patent Application,no,0,0,11,11,0,C07D401/14;;C07D403/04;;C07D405/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;C07D401/14;;C07D405/14;;C07D403/04,A61K31/506;;C07D401/14;;A61K31/5377;;A61P5/48;;A61P9/00;;A61P9/04;;A61P17/14;;A61P25/00;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;C07D403/04;;C07D405/14,,0,0,,,,DISCONTINUED
35,MX,A,MX 2007008373 A,164-202-811-784-877,2007-09-06,2007,MX 2007008373 A,2006-01-11,GB 0500492 A;;GB 2006000087 W,2005-01-11,4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY.,"The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof. The present invention seeks to provide further substituted heteroaryl-substituted pyrimidine derivatives. More specifically, the invention relates to compounds that have broad therapeutic applications in the treatment of a number of different diseases and/or that are capable of inhibiting one or more protein kinases.",CYCLACEL LTD,WANG SHUDONG;;DUNCAN KENNETH;;FISCHER PETER MARTIN;;MEADES CHRISTOPHER KEITH;;ANDREWS MARTIN JAMES INGLIS;;GIBSON DARREN,,https://lens.org/164-202-811-784-877,Patent Application,no,0,0,11,11,0,C07D401/14;;C07D403/04;;C07D405/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;C07D401/14;;C07D405/14;;C07D403/04,C07D401/14;;A61K31/506;;A61K31/5377;;A61P5/48;;A61P9/00;;A61P9/04;;A61P17/14;;A61P25/00;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;C07D403/04;;C07D405/14,,0,0,,,,DISCONTINUED
36,CN,A,CN 101111490 A,001-396-771-586-311,2008-01-23,2008,CN 200680003768 A,2006-01-11,GB 0500492 A,2005-01-11,4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy,,CYCLACEL LTD,MARTIN FISCHER PETER;;SHUDONG WANG;;KEITH MEADES CHRISTOPHER;;INGLIS ANDREWS MARTIN JAMES;;DARREN GIBSON;;KENNETH DUNCAN,,https://lens.org/001-396-771-586-311,Patent Application,no,0,7,11,11,0,C07D401/14;;C07D403/04;;C07D405/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;C07D401/14;;C07D405/14;;C07D403/04,C07D401/14;;A61K31/506;;A61K31/5377;;A61P5/48;;A61P9/00;;A61P9/04;;A61P17/14;;C07D403/04;;C07D405/14,,0,0,,,,DISCONTINUED
37,BR,A2,BR PI0606313 A2,032-287-544-191-661,2009-06-16,2009,BR PI0606313 A,2006-01-11,GB 0500492 A;;GB 2006000087 W,2005-01-11,"derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia","DERIVADOS DE 4-(1 H-INDOL-3-IL)-PIRIMIDIN-2-ILAMINA, PROCESSO PARA SUA PREPARAçãO E SEU USO EM TERAPIA. A presente invenção se refere a compostos de fórmula (1), ou sais dos mesmos farmaceuticamente aceitáveis. A presente invenção procura proporcionar derivados de pirimidina substituidos com heteroarila adicionalmente substituidos. Mais especificamente, a invenção se refere a compostos que têm amplas aplicações terapêuticas no tratamento de uma série de diferentes doenças e/ou que são capazes de inibir uma ou mais proteína quinases.",CYCLACEL LTD,FISCHER PETER MARTIN;;WANG SHUDONG;;MEADES CHRISTOPHER KEITH;;ANDREWS MARTIN JAMES INGLIS;;GIBSON DARREN;;DUNCAN KENNETH,,https://lens.org/032-287-544-191-661,Patent Application,no,0,0,11,11,0,C07D401/14;;C07D403/04;;C07D405/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;C07D401/14;;C07D405/14;;C07D403/04,A61K31/506;;C07D401/14;;A61K31/5377;;A61P5/48;;A61P9/00;;A61P9/04;;A61P17/14;;A61P25/00;;A61P29/00;;C07D403/04;;C07D405/14,,0,0,,,,DISCONTINUED
38,EP,A1,EP 1836194 A1,186-218-421-695-304,2007-09-26,2007,EP 06701760 A,2006-01-11,GB 2006000087 W;;GB 0500492 A,2005-01-11,4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY,,CYCLACEL LTD,FISCHER PETER MARTIN;;WANG SHUDONG;;MEADES CHRISTOPHER KEITH;;ANDREWS MARTIN JAMES INGLIS;;GIBSON DARREN;;DUNCAN KENNETH,,https://lens.org/186-218-421-695-304,Patent Application,yes,0,0,11,11,0,C07D401/14;;C07D403/04;;C07D405/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;C07D401/14;;C07D405/14;;C07D403/04,C07D401/14;;A61K31/506;;A61K31/5377;;A61P5/48;;A61P9/00;;A61P9/04;;A61P17/14;;A61P25/00;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;C07D403/04;;C07D405/14,,0,0,,,,DISCONTINUED
39,WO,A1,WO 2006/075152 A1,001-717-860-801-057,2006-07-20,2006,GB 2006000087 W,2006-01-11,GB 0500492 A,2005-01-11,4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY,"The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof. The present invention seeks to provide further substituted heteroaryl-substituted pyrimidine derivatives. More specifically, the invention relates to compounds that have broad therapeutic applications in the treatment of a number of different diseases and/or that are capable of inhibiting one or more protein kinases.",CYCLACEL LTD;;FISCHER PETER MARTIN;;WANG SHUDONG;;MEADES CHRISTOPHER KEITH;;ANDREWS MARTIN JAMES INGLIS;;GIBSON DARREN;;DUNCAN KENNETH,FISCHER PETER MARTIN;;WANG SHUDONG;;MEADES CHRISTOPHER KEITH;;ANDREWS MARTIN JAMES INGLIS;;GIBSON DARREN;;DUNCAN KENNETH,,https://lens.org/001-717-860-801-057,Patent Application,yes,2,68,11,11,0,C07D401/14;;C07D403/04;;C07D405/14;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P43/00;;A61P5/48;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;C07D401/14;;C07D405/14;;C07D403/04,A61K31/506;;C07D401/14;;A61K31/5377;;A61P5/48;;A61P9/00;;A61P9/04;;A61P17/14;;A61P25/00;;A61P29/00;;A61P31/00;;A61P33/00;;A61P35/00;;C07D403/04;;C07D405/14,,5,5,057-674-082-171-443;;009-584-629-665-579;;041-049-119-198-806;;087-096-337-051-045;;036-292-690-732-050,9748381;;10.1021/np970493u;;15026054;;10.1016/j.bmcl.2004.01.050;;10.1016/s0040-4020(01)00102-8;;10.1016/s0040-4039(00)00728-0;;10.3987/com-00-8890,"HERNANDEZ FRANCO, LAURA ET AL: ""Indole alkaloids from the Tunicate Aplidium meridianum"", JOURNAL OF NATURAL PRODUCTS , 61(9), 1130-1132 CODEN: JNPRDF; ISSN: 0163-3864, 1998, XP002367720;;GOMPEL, LEOST, JOFFE, PURICELLI, FRANCO, PALERMO, MEIJER: ""Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 1703 - 1707, XP002367721;;FRESNEDA, MOLINA, BLEDA: ""Synthesis of the indole alkaloids meridianins from the tunicate Aplidium meridianum"", TETRAHEDRON, vol. 57, 2001, pages 2355 - 2363, XP002367722;;FRESNEDA, MOLINA, DELGADO, BLEDA: ""Synthetic studies towards the 2-aminopyrimidine alkaloids variolins and meridianins from marine origin"", TETRAHEDRON LETTERS, vol. 41, 2000, pages 4777 - 4780, XP002367723;;BIAO JIANG, CAI-GUANG YANG: ""Synthesis of indolylpyrimidines via cross-coupling of indolylboronic acid with chloropyrimidines: Facile synthesis of meridianin D"", HETEROCYCLES, vol. 53, no. 7, 2000, pages 1489 - 1498, XP008060011",PENDING
40,WO,A2,WO 2007/042786 A2,008-828-112-866-185,2007-04-19,2007,GB 2006003751 W,2006-10-09,GB 0520955 A,2005-10-14,COMPOUND,"The present invention relates to compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof. Further aspects relate to pharmaceutical compositions comprising compounds according to the invention, and the use of said compounds in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.",CYCLACEL LTD;;WOOD GAVIN;;MEADES CHRISTOPHER KEITH;;FISCHER PETER;;WANG SHUDONG;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;MCINNES CAMPBELL;;THOMAS MARK,WOOD GAVIN;;MEADES CHRISTOPHER KEITH;;FISCHER PETER;;WANG SHUDONG;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;MCINNES CAMPBELL;;THOMAS MARK,,https://lens.org/008-828-112-866-185,Patent Application,yes,0,29,7,7,0,C07D401/14;;C07D403/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/28;;A61P27/02;;A61P27/06;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D401/14;;C07D403/04,A61K31/506;;A61P29/00;;A61P31/12;;A61P35/00;;C07D401/14;;C07D403/04,,0,0,,,,PENDING
41,EP,A2,EP 1945219 A2,031-245-579-104-255,2008-07-23,2008,EP 06794702 A,2006-10-09,GB 2006003751 W;;GB 0520955 A,2005-10-14,COMPOUND,,CYCLACEL LTD,WOOD GAVIN;;MEADES CHRISTOPHER KEITH;;FISCHER PETER;;WANG SHUDONG;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;MCINNES CAMPBELL;;THOMAS MARK,,https://lens.org/031-245-579-104-255,Patent Application,yes,0,0,7,7,0,C07D401/14;;C07D403/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/28;;A61P27/02;;A61P27/06;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D401/14;;C07D403/04,A61K31/506;;A61P29/00;;A61P31/12;;A61P35/00;;C07D401/14;;C07D403/04,,0,0,,,,DISCONTINUED
42,CN,A,CN 101325953 A,067-667-876-641-969,2008-12-17,2008,CN 200680045952 A,2006-10-09,GB 0520955 A,2005-10-14,4-heteroaryl-pyrimidine derivatives and use thereof as protein kinase inhibitors,"The present invention relates to compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof. Further aspects relate to pharmaceutical compositions comprising compounds according to the invention, and the use of said compounds in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.",CYCLACEL LTD,GAVIN WOOD;;KEITH MEADES CHRISTOPHER;;PETER FISCHER;;SHUDONG WANG;;KENNETH DUNCAN;;DANIELLA ZHELEVA;;CAMPBELL MCINNES;;MARK THOMAS,,https://lens.org/067-667-876-641-969,Patent Application,no,0,3,7,7,0,C07D401/14;;C07D403/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/28;;A61P27/02;;A61P27/06;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D401/14;;C07D403/04,A61K31/506;;A61P29/00;;A61P31/12;;A61P35/00;;C07D401/14;;C07D403/04,,0,0,,,,DISCONTINUED
43,US,A1,US 2024/0078294 A1,072-320-887-321-31X,2024-03-07,2024,US 18240336,2023-08-30,EP 22193529.9,2022-09-01,METHOD AND APPARATUS FOR INCREASING THE SECURITY OF SOFTWARE CODE THROUGH EXECUTION PATH DIVERSITY,"A system and method for creating secure software code. Original code is processed to determine memory states, which are dynamic during execution of the code. Selected functions of the code are duplicated and placed in parallel alternative control paths in order to create protected code with increased path diversity. The state of the memory, or a variable derived therefrom is used to select one of the alternative paths during execution of the protected code.",Irdeto B.V.,Peter MEERWALD-STADLER;;Matthaeus PUEHRINGER;;Leo RAUCH;;Wolfgang SCHÖCHL;;Duncan OGILVIE;;Matthias FISCHER;;Istvan NAGY;;Francesco MAURI,,https://lens.org/072-320-887-321-31X,Patent Application,yes,0,0,1,1,0,G06F21/12;;G06F8/35,G06F21/12;;G06F8/35,,0,0,,,,UNKNOWN
44,WO,A3,WO 2007/042786 A3,058-605-064-074-399,2007-06-07,2007,GB 2006003751 W,2006-10-09,GB 0520955 A,2005-10-14,4 -HETEROARYL PYRIMIDINE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS,"The present invention relates to compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof. Further aspects relate to pharmaceutical compositions comprising compounds according to the invention, and the use of said compounds in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.",CYCLACEL LTD;;WOOD GAVIN;;MEADES CHRISTOPHER KEITH;;FISCHER PETER;;WANG SHUDONG;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;MCINNES CAMPBELL;;THOMAS MARK,WOOD GAVIN;;MEADES CHRISTOPHER KEITH;;FISCHER PETER;;WANG SHUDONG;;DUNCAN KENNETH;;ZHELEVA DANIELLA;;MCINNES CAMPBELL;;THOMAS MARK,,https://lens.org/058-605-064-074-399,Search Report,yes,8,0,7,7,0,C07D401/14;;C07D403/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/28;;A61P27/02;;A61P27/06;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D401/14;;C07D403/04,A61K31/506;;A61P29/00;;A61P31/12;;A61P35/00;;C07D401/14;;C07D403/04,,1,1,051-068-366-197-081,15261277;;10.1016/j.bmcl.2004.06.012,"WANG S. ET AL.: ""Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl)pyrimidine CDK inhibitors"", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 4237 - 4240, XP002429038",PENDING
45,US,A1,US 2009/0215805 A1,088-862-592-753-809,2009-08-27,2009,US 8355906 A,2006-10-09,GB 0520955 A;;GB 2006003751 W,2005-10-14,4-Heteroaryl Pyrimidine Derivatives and use thereof as Protein Kinase Inhibitors,"The present invention relates to compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof. Further aspects relate to pharmaceutical compositions comprising compounds according to the invention, and the use of said compounds in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.",CYCLACEL LTD,WOOD GAVIN;;MEADES CHRISTOPHER;;FISCHER PETER MARTIN;;WANG SHUDONG;;DUNCAN KENNETH;;ZHELEVA DANIELLA I;;MCINNES CAMPBELL;;THOMAS MARK,,https://lens.org/088-862-592-753-809,Patent Application,yes,13,10,7,7,0,C07D401/14;;C07D403/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/28;;A61P27/02;;A61P27/06;;A61P29/00;;A61P31/12;;A61P31/18;;A61P31/22;;A61P35/00;;A61P35/02;;A61P43/00;;A61P3/10;;C07D401/14;;C07D403/04,A61K31/506;;A61P3/10;;A61P25/28;;A61P35/00;;C07D239/02;;G01N33/53;;G01N33/566,514/275;;544/297;;436/501;;435/7.1,0,0,,,,DISCONTINUED
46,WO,A1,WO 2012/028773 A1,046-080-326-497-363,2012-03-08,2012,FI 2011050739 W,2011-08-25,US 87420610 A,2010-09-01,MODE SWITCHING,"Based on one or more characteristics of a received translation input, a computing device is switched between two or more states. The translation input may be a touch input, for example a drag operation. The states may relate to locked and unlocked states, idle screens, or other suitable examples.",NOKIA CORP;;LAMB DUNCAN;;MOLTONI THOMAS;;FISCHER DANIEL;;PUGH PAUL;;YU PAUL;;VOEGE NINA;;MARTIN JOHN;;BOROVSKY ANDREW;;LIN ANDREW,LAMB DUNCAN;;MOLTONI THOMAS;;FISCHER DANIEL;;PUGH PAUL;;YU PAUL;;VOEGE NINA;;MARTIN JOHN;;BOROVSKY ANDREW;;LIN ANDREW,,https://lens.org/046-080-326-497-363,Patent Application,yes,6,80,44,44,0,G06F3/04883;;G06F3/04883;;G06F3/04883;;G06F3/0412;;G06F3/0416;;G06F3/0486;;G06F3/0486;;G06F2203/04808,G06F3/048;;G06F21/00,,1,0,,,See also references of EP 2598983A4,PENDING
47,CA,A1,CA 2488816 A1,098-588-276-528-101,2004-01-15,2004,CA 2488816 A,2003-07-07,GB 0215650 A;;GB 0302923 W,2002-07-05,BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY,"The present invention relates to the use of bisarylsulfonamide compounds of formula (I) wherein W is a CI-5 branched or unbranched alkyl group or a C2- 5alkenyl group; nis0or1; R1 is H, a C, 1-8 branched or unbranched alkyl grou p, a C2-8 alkenyl group, or an aryl or aralkyl group; Ar1 is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar2 is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Furthe r aspects of the invention relate to compounds of formula (I), pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,MACCALLUM DAVID;;FISCHER PETER MARTIN;;THOMAS MARK;;BAILEY KEVIN;;ZHELEVA DANIELLA;;WANG SHUDONG;;TURNER NICHOLAS JOHN;;DUNCAN KENNETH;;GIBSON DARREN,,https://lens.org/098-588-276-528-101,Patent Application,no,0,0,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,0,0,,,,DISCONTINUED
48,DE,D1,DE 60316686 D1,175-263-884-713-306,2007-11-15,2007,DE 60316686 T,2003-07-07,GB 0215650 A;;GB 0302923 W,2002-07-05,BISARYLSULFONAMID-DERIVATE UND IHRE VERWENDUNG FÜR KREBS THERAPIE,"The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C<SUB>1-5 </SUB>branched or unbranched alkyl group or a C<SUB>2-5 </SUB>alkenyl group; n is 0 or 1; R<SUP>1 </SUP>is H, a C<SUB>1-8 </SUB>branched or unbranched alkyl group, a C<SUB>2-8 </SUB>alkenyl group, or an aryl or aralkyl group; Ar<SUP>1 </SUP>is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar<SUP>2 </SUP>is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN,,https://lens.org/175-263-884-713-306,Granted Patent,no,0,0,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,C07D333/42;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,0,0,,,,EXPIRED
49,EP,A1,EP 1519932 A1,051-155-639-973-732,2005-04-06,2005,EP 03738323 A,2003-07-07,GB 0302923 W;;GB 0215650 A,2002-07-05,BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY,"The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C<SUB>1-5 </SUB>branched or unbranched alkyl group or a C<SUB>2-5 </SUB>alkenyl group; n is 0 or 1; R<SUP>1 </SUP>is H, a C<SUB>1-8 </SUB>branched or unbranched alkyl group, a C<SUB>2-8 </SUB>alkenyl group, or an aryl or aralkyl group; Ar<SUP>1 </SUP>is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar<SUP>2 </SUP>is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN,CYCLACEL LIMITED (2005-06-08),https://lens.org/051-155-639-973-732,Patent Application,yes,0,6,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,0,0,,,,EXPIRED
50,WO,A1,WO 2004/005278 A1,094-856-322-596-82X,2004-01-15,2004,GB 0302923 W,2003-07-07,GB 0215650 A,2002-07-05,BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY,"The present invention relates to the use of bisarylsulfonamide compounds of formula (I) wherein W is a CI-5 branched or unbranched alkyl group or a C2-5 alkenyl group; nis0or1; R1 is H, a C, 1-8 branched or unbranched alkyl group, a C2-8 alkenyl group, or an aryl or aralkyl group; Ar1 is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar2 is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula (I), pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD;;WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN,WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN,,https://lens.org/094-856-322-596-82X,Patent Application,yes,6,22,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,19,14,041-422-442-235-032;;009-619-505-738-315;;085-549-887-670-242;;043-081-783-557-056;;111-272-962-149-53X;;007-855-030-339-987;;032-574-518-383-880;;002-381-276-055-868;;060-906-131-165-399;;018-613-448-666-907;;013-568-990-634-233;;005-167-416-050-586;;002-461-701-510-703;;042-048-700-628-154,10.1080/03086648208078988;;14163980;;10.1111/j.2042-7158.1964.tb07439.x;;6268120;;6644743;;10.1021/jm00366a016;;10.1039/p19740000903;;10.1021/jf60209a045;;1002940;;10.1039/jr9300001071;;10.1002/hlca.193902201114;;10.1039/jr9440000632;;10.1039/jr9580002079;;10.1002/jlac.19355200103;;4372263;;10.1021/jf60196a026;;10.1016/s0040-4020(01)81037-1;;9767646;;10.1021/jm9802012,"C. A. OBAFEMI: ""Studies in the Heterocyclic Compounds V. Some Reactions of 5-Chloro-2-thiophenesulfonyl Derivatives."", PHOSPHORUS AND SULFUR, vol. 13, 1982, pages 119 - 31, XP009011599;;M. ONO ET. AL.: ""Pyrimidines. V. Smiles Rearrangement of N'-(p-Nitrobenzenesulfonyl)-N1-N2-diarylacetamides."", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 38, no. 5, 1990, pages 1373 - 8, XP001155293;;V. N. MIKHAILOVA ET. AL.: ""Synthesis and Properties of some Arenesulfonamides."", JOURNAL OF GENERAL CHEMISTRY OF THE USSR /(ENGLISH TRANS.),, vol. 46, 1976, pages 876 - 7, XP009018771;;I. KH. FELDMAN ET. AL.: ""Amidosulfones and Aminosulfones XXVI. Synthesis of Some Derivatives of 2-Methyl-5-nitro-and 4-Methyl-3-nitro-Benzenesulfonic Acids."", JOURNAL OF GENERAL CHEMISTRY OF THE USSR (ENGLISH TRANS), vol. 33, 1963, pages 33 - 37, XP009018772;;G. DAUPHIN ET. AL.: ""Application de l'étude de la dissociation acids de sulfonamides à des problèmes de structure."", BULLETIN OF THE CHEMICAL SOCIETY OF FRANCE, vol. 1967, 1967, pages 3395 - 3404, XP001031257;;B. H. CHASE ET. AL.: ""The Synthesis of Some Potential Antibacterial Agents."", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 16, 1964, pages 163 - 73, XP001040339;;N. NEYKOVA ET. AL.: ""Benzoxalone-5-sulfonamides, 1-(Benzoxazolone-5'-sulfonyl)-benzotriazoles and 4-Hydroxy-3,2'-diaminobenzenesulfonamides with Antiviral Activity"", ARZNEIMITTEL FORSCHUNG, vol. 31, 1981, pages 747 - 52, XP001155294;;W.M. LINFIELD ET.AL.: ""Antibacterially Active Substituted Anilides of Carboxylic and Sulfonic Acids"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 12, 1983, pages 1741 - 6, XP001155296;;G. P. ELLIS ET. AL.: ""One-step Synthesis and Spectral Study of Some 1-Methylbenzimidazoles including Use of a Lanthanide Shift Reagent."", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANS. I,, vol. 1974, 1974, pages 903 - 9, XP000655190;;G. DAUPHIN ET. AL.: ""Etude de la dissociation acide de quelques sulfonamides"", BULLETIN OF THE CHEMICAL SOCIETY OF FRANCE, vol. 1961, 1961, pages 486 - 92, XP009018774;;A. B. DE MILO ET. AL.: ""Insect Chemosterilants. Analogues of 2,5-Dichloro-N-(2,4-dinitrophenyl)-benzenesulfonamide."", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 25, no. 1, 1977, pages 81 - 3, XP009018762;;F. BELL: ""Investigations in the Diphenyl Series. Part IX. Further experiments with Sulphonamides."", JOURNAL OF THE CHEMICAL SOCIETY, vol. 1930, 1930, pages 1071 - 7, XP009018773;;C. NAEGLI ET. AL.: ""Pyridon-2-sulfonsäure-5-amid und Einige Abkömmlinge"", HELVETICA CHIMICA ACTA, vol. 22, 1939, pages 912 - 20, XP009020342;;D. F. ELLIOTT ET. AL.: ""Studies in the Indole Series. Part IV. Sulphonamides Derived from Indole."", JOURNAL OF THE CHEMICAL SOCIETY, vol. 1944, 1944, pages 632 - 3, XP009020348;;S. WILKINSON: ""5-Methoxy-N-methyltryptamine. A New Indole Alkaloid from Phalaris arundinacea"", JOURNAL OF THE CHEMICAL SOCIETY, vol. 1958, 1958, pages 2079 - 81, XP009020347;;T. HOSHINO ET. AL.: ""Synthese des d,l-Eseräthols"", JUSTUS LIEBIGS ANNALEN DER CHEMIE, vol. 520, 1935, pages 11-17, XP009020349;;A. SPINELLI ET. AL.: ""Effects of Processing on the Amine Content of Pork Bellies"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 22, 1974, pages 1026 - 8, XP009020346;;G. PALMISANO ET. AL.: ""Synthetic Studies on Indole Alkaloids. A Stereocontrolled Entry to the Cuanzine Structural Unit"", TETRAHEDRON, vol. 45, 1989, pages 3583 - 96, XP002029549;;E. ARRANZ ET. AL.: ""Novel 1,1,3-Trioxo-2H-4H-thieno[4,3-e]thiadiazine Derivatives as Non Nuclotide Reverse Transcriptase Inhibitors That Inhibit HIV Type 1 Replication"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 1998, pages 4109 - 17, XP002179390",PATENTED
51,EP,B1,EP 1519932 B1,185-268-782-242-780,2007-10-03,2007,EP 03738323 A,2003-07-07,GB 0302923 W;;GB 0215650 A,2002-07-05,BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY,"The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C<SUB>1-5 </SUB>branched or unbranched alkyl group or a C<SUB>2-5 </SUB>alkenyl group; n is 0 or 1; R<SUP>1 </SUP>is H, a C<SUB>1-8 </SUB>branched or unbranched alkyl group, a C<SUB>2-8 </SUB>alkenyl group, or an aryl or aralkyl group; Ar<SUP>1 </SUP>is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar<SUP>2 </SUP>is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN,CYCLACEL LIMITED (2005-06-08),https://lens.org/185-268-782-242-780,Granted Patent,yes,6,1,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,C07D333/42;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,19,0,,,"C. A. OBAFEMI: ""Studies in the Heterocyclic Compounds V. Some Reactions of 5-Chloro-2-thiophenesulfonyl Derivatives."" PHOSPHORUS AND SULFUR, vol. 13, 1982, pages 119-31, XP009011599;;M. ONO ET. AL.: ""Pyrimidines. V. Smiles Rearrangement of N'-(p-Nitrobenzenesulfonyl)-N1-N2-diarylac etamides. "" CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 38, no. 5, 1990, pages 1373-8, XP001155293;;V. N. MIKHAILOVA ET. AL.: ""Synthesis and Properties of some Arenesulfonamides."" JOURNAL OF GENERAL CHEMISTRY OF THE USSR /(ENGLISH TRANS.), , vol. 46, 1976, pages 876-7, XP009018771;;I. KH. FELDMAN ET. AL. : ""Amidosulfones and Aminosulfones XXVI. Synthesis of Some Derivatives of 2-Methyl-5-nitro-and 4-Methyl-3-nitro-Benzenesulfonic Acids. "" JOURNAL OF GENERAL CHEMISTRY OF THE USSR (ENGLISH TRANS) , vol. 33, 1963, pages 33-37, XP009018772;;G. DAUPHIN ET. AL.: ""Application de l'étude de la dissociation acids de sulfonamides à des problèmes de structure."" BULLETIN OF THE CHEMICAL SOCIETY OF FRANCE , vol. 1967, 1967, pages 3395-3404, XP001031257;;B. H. CHASE ET. AL.: ""The Synthesis of Some Potential Antibacterial Agents. "" JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 16, 1964, pages 163-73, XP001040339;;N. NEYKOVA ET. AL.: ""Benzoxalone-5-sulfonamides, 1-(Benzoxazolone-5'-sulfonyl)-benzotriazol es and 4-Hydroxy-3,2'-diaminobenzenesulfonamides with Antiviral Activity"" ARZNEIMITTEL FORSCHUNG, vol. 31, 1981, pages 747-52, XP001155294;;W.M. LINFIELD ET.AL.: ""Antibacterially Active Substituted Anilides of Carboxylic and Sulfonic Acids"" JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 12, 1983, pages 1741-6, XP001155296;;G. P. ELLIS ET. AL.: ""One-step Synthesis and Spectral Study of Some 1-Methylbenzimidazoles including Use of a Lanthanide Shift Reagent. "" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANS. I,, vol. 1974, 1974, pages 903-9, XP000655190;;G. DAUPHIN ET. AL. : ""Etude de la dissociation acide de quelques sulfonamides"" BULLETIN OF THE CHEMICAL SOCIETY OF FRANCE, vol. 1961, 1961, pages 486-92, XP009018774;;A. B. DE MILO ET. AL.: ""Insect Chemosterilants. Analogues of 2,5-Dichloro-N-(2,4-dinitrophenyl)-benzene sulfonamide. "" JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 25, no. 1, 1977, pages 81-3, XP009018762;;F. BELL: ""Investigations in the Diphenyl Series. Part IX. Further experiments with Sulphonamides. "" JOURNAL OF THE CHEMICAL SOCIETY, vol. 1930, 1930, pages 1071-7, XP009018773;;C. NAEGLI ET. AL. : ""Pyridon-2-sulfonsäure-5-amid und Einige Abkömmlinge"" HELVETICA CHIMICA ACTA, vol. 22, 1939, pages 912-20, XP009020342;;D. F. ELLIOTT ET. AL. : ""Studies in the Indole Series. Part IV. Sulphonamides Derived from Indole. "" JOURNAL OF THE CHEMICAL SOCIETY, vol. 1944, 1944, pages 632-3, XP009020348;;S. WILKINSON: ""5-Methoxy-N-methyltryptamine. A New Indole Alkaloid from Phalaris arundinacea"" JOURNAL OF THE CHEMICAL SOCIETY, vol. 1958, 1958, pages 2079-81, XP009020347;;T. HOSHINO ET. AL. : ""Synthese des d,l-Eseräthols"" JUSTUS LIEBIGS ANNALEN DER CHEMIE, vol. 520, 1935, page 11-17 XP009020349;;A. SPINELLI ET. AL.: ""Effects of Processing on the Amine Content of Pork Bellies "" JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 22, 1974, pages 1026-8, XP009020346;;G. PALMISANO ET. AL.: ""Synthetic Studies on Indole Alkaloids. A Stereocontrolled Entry to the Cuanzine Structural Unit "" TETRAHEDRON, vol. 45, 1989, pages 3583-96, XP002029549;;E. ARRANZ ET. AL.: ""Novel 1,1,3-Trioxo-2H-4H-thieno[4,3-e]thiadiazin e Derivatives as Non Nuclotide Reverse Transcriptase Inhibitors That Inhibit HIV Type 1 Replication "" JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 1998, pages 4109-17, XP002179390",EXPIRED
52,DE,T2,DE 60316686 T2,172-258-690-246-943,2008-01-24,2008,DE 60316686 T,2003-07-07,GB 0215650 A;;GB 0302923 W,2002-07-05,BISARYLSULFONAMID-DERIVATE UND IHRE VERWENDUNG FÜR KREBS THERAPIE,"The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C<SUB>1-5 </SUB>branched or unbranched alkyl group or a C<SUB>2-5 </SUB>alkenyl group; n is 0 or 1; R<SUP>1 </SUP>is H, a C<SUB>1-8 </SUB>branched or unbranched alkyl group, a C<SUB>2-8 </SUB>alkenyl group, or an aryl or aralkyl group; Ar<SUP>1 </SUP>is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar<SUP>2 </SUP>is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN,,https://lens.org/172-258-690-246-943,Granted Patent,no,0,0,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,C07D333/42;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,0,0,,,,EXPIRED
53,AT,T1,AT E374763 T1,006-328-853-753-213,2007-10-15,2007,AT 03738323 T,2003-07-07,GB 0215650 A,2002-07-05,BISARYLSULFONAMID-DERIVATE UND IHRE VERWENDUNG FÜR KREBS THERAPIE,"The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C<SUB>1-5 </SUB>branched or unbranched alkyl group or a C<SUB>2-5 </SUB>alkenyl group; n is 0 or 1; R<SUP>1 </SUP>is H, a C<SUB>1-8 </SUB>branched or unbranched alkyl group, a C<SUB>2-8 </SUB>alkenyl group, or an aryl or aralkyl group; Ar<SUP>1 </SUP>is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar<SUP>2 </SUP>is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN,,https://lens.org/006-328-853-753-213,Granted Patent,no,0,0,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,0,0,,,,EXPIRED
54,NZ,A,NZ 536494 A,023-638-376-536-610,2006-10-27,2006,NZ 53649403 A,2003-07-07,GB 0215650 A;;GB 0302923 W,2002-07-05,Bisarylsulfonamide compounds and their use in cancer therapy,"Disclosed are compounds of formula I and uses of compounds of formula I in the preparation of medicaments for treating proliferative disorders, wherein: W is alkylene or alkenylene, n is 0 or 1, R1 is H, alkyl, alkenyl, or optionally substituted aryl or aralkyl, and the remaining substituents are defined herein.",CYCLACEL LTD,WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN,,https://lens.org/023-638-376-536-610,Patent Application,no,0,0,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,0,0,,,,PENDING
55,AU,A1,AU 2003/244847 A1,041-968-147-434-201,2004-01-23,2004,AU 2003/244847 A,2003-07-07,GB 0215650 A;;GB 0302923 W,2002-07-05,BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY,"The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C<SUB>1-5 </SUB>branched or unbranched alkyl group or a C<SUB>2-5 </SUB>alkenyl group; n is 0 or 1; R<SUP>1 </SUP>is H, a C<SUB>1-8 </SUB>branched or unbranched alkyl group, a C<SUB>2-8 </SUB>alkenyl group, or an aryl or aralkyl group; Ar<SUP>1 </SUP>is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar<SUP>2 </SUP>is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA;;TURNER NICHOLAS JOHN;;FISCHER PETER MARTIN;;WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN,,https://lens.org/041-968-147-434-201,Patent Application,no,0,0,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,0,0,,,,DISCONTINUED
56,CN,A,CN 1665802 A,066-958-657-195-19X,2005-09-07,2005,CN 03815948 A,2003-07-07,GB 0215650 A,2002-07-05,Bisarylsulfonamide compounds and their use in cancer therapy,"The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C<SUB>1-5 </SUB>branched or unbranched alkyl group or a C<SUB>2-5 </SUB>alkenyl group; n is 0 or 1; R<SUP>1 </SUP>is H, a C<SUB>1-8 </SUB>branched or unbranched alkyl group, a C<SUB>2-8 </SUB>alkenyl group, or an aryl or aralkyl group; Ar<SUP>1 </SUP>is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; and Ar<SUP>2 </SUP>is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,SHUDONG WANG;;DARREN GIBSON;;KENNETH DUNCAN;;KEVIN BAILEY;;MARK THOMAS;;DAVID MACCALLUM;;ZHELEVA DANIELLA I;;TURNER NICHOLAS J;;FISCHER PETER M,,https://lens.org/066-958-657-195-19X,Patent Application,no,0,2,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,,0,0,,,,DISCONTINUED
57,US,A1,US 2005/0215548 A1,185-252-289-517-764,2005-09-29,2005,US 98838804 A,2004-11-12,US 98838804 A;;GB 0215650 A;;GB 0302923 W,2002-07-05,Bisarylsulfonamide compounds and their use in cancer therapy,"The present invention relates to the use of bisarylsulfonamide compounds of formula I wherein W is a C 1-5 branched or unbranched alkyl group or a C 2-5 alkenyl group; n is 0 or 1;R 1 is H, a C 1-8 branched or unbranched alkyl group, a C 2-8 alkenyl group, or an aryl or aralkyl group;Ar 1 is a substituted thienyl, furyl, pyrrolyl, imidazothiazolyl, thiazolyl, pyridyl or phenyl group; andAr 2 is a substituted phenyl, indolyl or benzoimidazolyl group; in the preparation of a medicament for treating proliferative disorders. Further aspects of the invention relate to compounds of formula I, pharmaceutical compositions thereof, and an assay for determining binding to HDM2.",CYCLACEL LTD,WANG SHUDONG;;GIBSON DARREN;;DUNCAN KENNETH;;BAILEY KEVIN;;THOMAS MARK;;MACCALLUM DAVID;;ZHELEVA DANIELLA I;;TURNER NICHOLAS J;;FISCHER PETER M,CYCLACEL LIMITED (2005-04-28),https://lens.org/185-252-289-517-764,Patent Application,yes,5,40,14,14,0,C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04;;A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D207/34;;C07D209/14;;C07D213/71;;C07D277/36;;C07D285/10;;C07D413/04;;A61P11/00;;A61P13/12;;A61P17/06;;A61P17/14;;A61P29/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/00;;A61P43/00;;A61P9/10;;C07D213/70;;C07D409/04;;C07C311/21;;C07D209/16;;C07D333/62;;C07D333/42;;C07C311/44;;C07D235/30;;C07C311/29;;C07D277/56;;C07D513/04;;C07D263/32;;C07D295/185;;C07D207/36;;C07D231/12;;C07D285/06;;C07D333/34;;C07D409/12;;C07D319/18;;C07D207/34;;C07D285/10;;A61K31/454;;C07D277/36;;C07D413/04;;C07D209/14;;C07D213/71;;A61K31/43;;A61K31/4439;;A61K31/5377,A61K31/43;;A61K31/4439;;A61K31/454;;A61K31/5377;;A61P35/00;;C07C311/21;;C07C311/29;;C07C311/44;;C07D207/36;;C07D209/16;;C07D213/70;;C07D231/12;;C07D235/30;;C07D263/32;;C07D277/56;;C07D285/06;;C07D295/185;;C07D319/18;;C07D333/34;;C07D333/42;;C07D333/62;;C07D409/04;;C07D409/12;;C07D513/04,514/235.2;;514/338;;514/366;;514/414;;514/322;;514/323;;514/406,0,0,,,,DISCONTINUED
58,CN,B,CN 1898237 B,082-823-689-233-754,2011-08-10,2011,CN 200480038336 A,2004-10-21,GB 2004004465 W;;GB 0324599 A;;GB 0330013 A,2003-10-21,"Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy","The present invention relates to compounds of formula: (I), or pharmaceutically acceptable salts thereof, wherein R<1> and R<5> are each independently H, C(OR<j'>) or a hydrocarbyl group optionally substituted by one or more R<6> groups; R<2>, R<3>, and R<4> are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R<7> groups; R<6> and R<7> are eachindependently halogen, NO2, CN, (CH2)mOR<a>, O(CH2)nOR<b>, (CH2)pNR<c>R<d>, CF3, COOR<e>, CONR<f>R<g>, COR<h>, SO3H, SO2R , SO2NR<j>R<k>, (CH2)qNR<a'>COR<g'>, R<f'>, (CH2)rNR<b'>SO2R<h'>, SO2NR<d'>R<i'>, SO2NR<e'>(CH2)s,OR<c'>, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, R<m> and COR<n>; R<g'>, R<h'>, R<i'> and R<j'> are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3; n and s are each independently 1, 2, or 3; and R<a-n> and R<a'-f'> are each independently H or alkyl. Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.",CYCLACEL LTD,FISCHER PETER M;;ZHELEVA DANIELLA I;;JANICE MCLACHLAN;;DARREN GIBSON;;SHUDONG WANG;;CHRISTOPHER MEADES;;ALEX PERRY;;GAVIN WOOD;;KENNETH DUNCAN;;DAVID BLAKE,,https://lens.org/082-823-689-233-754,Granted Patent,no,0,0,3,15,0,,C07D417/14;;A61K31/506;;C07D417/04,,0,0,,,,INACTIVE
59,US,A1,US 2007/0021452 A1,158-806-556-644-251,2007-01-25,2007,US 40846306 A,2006-04-21,GB 0324599 A;;GB 0330013 A;;GB 2004004465 W,2003-10-21,"Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy","The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R 1 and R 5 are each independently H, C(OR j′ ) or a hydrocarbyl group optionally substituted by one or more R 6 groups; R 2 , R 3 , and R 4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R 7 groups; R 6 and R 7 are each independently halogen, NO 2 , CN, (CH 2 ) m OR a , O(CH 2 ) n OR b , (CH 2 ) p NR c R d , CF 3 , COOR e , CONR f R g , COR h , SO 3 H, SO 2 R i , SO 2 NR j R k , (CH 2 ) q NR a′ COR g′ , R f′ , (CH 2 ) r NR b′ SO 2 R h′ , SO 2 NR d′ R i′ , SO 2 NR e′ (CH 2 ) s OR c′ , heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, R m and COR n ; R g′ , R h′ , R i′ and R j′ are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO 2 , NH 2 CF 3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3; n and s are each independently 1, 2, or 3; and R a-n and R a′-f′ are each independently H or alkyl. Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.",CYCLACEL LTD,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE;;PERRY ALEX;;BLAKE DAVID;;ZHELEVA DANIELLA I;;FISCHER PETER M,CYCLACEL LIMITED (2006-06-30),https://lens.org/158-806-556-644-251,Patent Application,yes,9,26,11,15,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,A61K31/506;;C07D417/04;;C07D417/14,514/275;;544/331,0,0,,,,INACTIVE
60,US,B2,US 7902361 B2,163-936-828-934-110,2011-03-08,2011,US 40846306 A,2006-04-21,GB 0324599 A;;GB 0330013 A;;GB 2004004465 W,2003-10-21,"Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy","The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R 1 and R 5 are each independently H, C(OR j′ ) or a hydrocarbyl group optionally substituted by one or more R 6 groups; R 2 , R 3 , and R 4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R 7 groups;R 6 and R 7 are each independently halogen, NO 2 , CN, (CH 2 ) m OR a , O(CH 2 ) n OR b , (CH 2 ) p NR c R d , CF 3 , COOR e , CONR f R g , COR h , SO 3 H, SO 2 R i , SO 2 NR j R k , (CH 2 ) q NR a′ COR g′ , R f′ , (CH 2 ) r NR b′ SO 2 R h′ , SO 2 NR d′ R i′ , SO 2 NR e′ (CH 2 ) s OR c′ , heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, R m and COR n ;R g′ , R h′ , R i′ and R j′ are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO 2 , NH 2 CF 3 and COOH;m, p, q and r are each independently 0, 1, 2 or 3;n and s are each independently 1, 2, or 3; andR a-n and R a′-f′ are each independently H or alkyl. Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.",CYCLACEL LTD,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE;;PERRY ALEX;;BLAKE DAVID;;ZHELEVA DANIELLA I;;FISCHER PETER MARTIN,CYCLACEL LIMITED (2006-06-30),https://lens.org/163-936-828-934-110,Granted Patent,yes,14,6,11,15,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D403/04;;A61K31/506;;A61P3/10;;A61P19/02;;A61P35/02;;C07D403/14;;C07D417/04;;C07D417/14,544/331;;514/275;;514/235.8;;514/252.14;;544/295;;544/122,40,10,024-966-713-830-730;;137-766-965-938-562;;102-382-641-707-386;;167-921-090-291-422;;103-408-031-771-646;;073-733-057-359-302;;076-982-286-123-64X;;001-062-006-753-530;;061-723-542-478-730;;004-281-107-280-815,10.1016/j.tibs.2005.09.005;;16236519;;10.4161/cc.4.4.1607;;10.1101/gad.1256504;;15545627;;10.4161/cc.3.6.937;;9325318;;10.1074/jbc.272.41.25863;;10.2741/a529;;10799356;;10.1042/bst0320803;;15494020;;pmc4485494;;10.1016/j.tibs.2003.12.004;;15102436;;14967453;;10.1016/j.ijrobp.2003.09.093;;12191602;;10.1016/s0163-7258(02)00179-1,"Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.;;Malumbres et al., Trends in Biochemical Sciences, 30(11), 630-641, 2005.;;Lolli et al., Cell Cycle 4:4,572-577, 2005.;;Sherr et al., Genes & Development 18, 2699-2711,2004.;;Fischer Cell Cycle 3:6, 742-746, 2004.;;Blain et al., The Journal of Biological Chemistry, 272(41), 25863-25872, 1997.;;LuValle et al., Frontiers in Bioscience, 5, d493-503,2000.;;Patel et al. Biochem. Soc. Trans. 32(5), 803-808,2004.;;Jope et al., Trends in Biochemical Sciences 29(2), 95-102, 2004.;;Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.;;Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.;;U.S. Appl. No. 10/646,267, filed Aug. 22, 2003.;;U.S. Appl. No. 10/153,441, filed May 21, 2002.;;U.S. Appl. No. 10/671,747, filed Sep. 26, 2003.;;U.S. Appl. No. 11/507,929, filed Aug. 21, 2006.;;U.S. Appl. No. 10/671,747, filed Sep. 24, 2003.;;U.S. Appl. No. 10/742,237, filed Dec. 18, 2003.;;U.S. Appl. No. 10/810,767, filed Mar. 26, 2004.;;U.S. Appl. No. 11/433,312, filed May 11, 2006.;;U.S. Appl. No. 10/846,217, filed May 14, 2004.;;U.S. Appl. No. 10/914,842, filed Aug. 10, 2004.;;U.S. Appl. No. 10/991,942, filed Nov. 17, 2004.;;U.S. Appl. No. 10/507,883, filed Sep. 15, 2004.;;U.S. Appl. No. 10/952,575, filed Sep. 27, 2004.;;U.S. Appl. No. 11/033,692, filed Jan. 11, 2005.;;U.S. Appl. No. 11/238,533, filed Sep. 28, 2005.;;U.S. Appl. No. 11/051,059, filed Feb. 4, 2005.;;U.S. Appl. No. 11/124,636, filed May 5, 2005.;;U.S. Appl. No. 11/122,331, filed May 3, 2005.;;U.S. Appl. No. 11/121,753, filed May 3, 2005.;;U.S. Appl. No. 11/124,622, filed May 5, 2005.;;U.S. Appl. No. 11/140,136, filed May 26, 2005.;;U.S. Appl. No. 11/129,198, filed May 13, 2005.;;U.S. Appl. No. 11/192,893, filed Jul. 28, 2005.;;U.S. Appl. No. 11/301,070, filed Dec. 9, 2005.;;U.S. Appl. No. 11/326,805, filed Jan. 6, 2006.;;U.S. Appl. No. 11/339,058, filed Jan. 25, 2006.;;U.S. Appl. No. 11/339,059, filed Jan. 25, 2006.;;U.S. Appl. No. 10/588,372, filed Aug. 3, 2006.;;International Search Report for PCT/GB2004/004465, dated Apr. 24, 2006.",INACTIVE
61,BR,A,BR PI0415759 A,093-553-908-489-875,2006-12-19,2006,BR PI0415759 A,2004-10-21,GB 0324599 A;;GB 0330013 A;;GB 2004004465 W,2003-10-21,"compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia","""COMPOSTOS DE PIRIMIDIN-4-IL-3,4-TIONA E USO DOS MESMOS NA TERAPIA"". A presente invenção refere-se aos compostos da fórmula: (I) ou sais farmaceuticamente aceitáveis dos mesmos, em que R¬ 1¬ e R¬ 5¬ São Cada um independentemente H, C(OR¬ j¬<39>) ou um grupo hidrocarbila opcionalmente substituído por um ou mais grupos R¬ 6¬; R¬ 2¬, R¬ 3¬ e R¬ 4¬ São cada um independentemente H, alquila ou alquenila, cada um dos quais pode ser opcionalmente substituído por um ou mais grupos R¬ 7¬; R¬ 6¬ e R¬ 7¬ São cada um independentemente halogênio, NO~ 2~, CN, (CH~ 2~)~ m~OR¬ a¬, O(CH~ 2~)~ n~OR¬ b¬ (CH~ 2~)~ p~NR¬ c¬R¬ d¬, CF~ 3~, COOR¬ e¬CONR¬ f¬R¬ g¬, COR¬ h¬, SO~ 3~H, SO~ 2~R¬ i¬, SO~ 2~NR¬ j¬R¬ k¬, (CH~ 2~)~ q~NR¬ a¬<39>COR¬ g¬<39>, R¬ f¬, (CH~ 2~)~ r~NR¬ b¬<39>SO~ 2~R¬ h¬<39>, SO~ 2~NR¬ d¬<39>R¬ i¬<39>, SO~ 2~NR¬ e¬ <39>(CH~ 2~)~ s~OR¬ c¬<39>, heterociclila ou heteroarila, em que o dito heterociclila e heteroarila podem ser opcionalmente substituídos por um ou mais substituintes selecionados de aralquila, sulfonila, R¬ m¬ e COR¬ n¬; R¬ g¬<39>, R¬ h¬<39>, R¬ i¬<39> e R¬ j¬<39> são cada um independentemente selecionados de alquila, arila, aralquila e heteroarila, cada um dos quais pode ser opcionalmente substituído por um ou mais substituintes selecionados de halogênio, OH, NO~ 2~, NH~ 2~ CF~ 3~ e COOH; m, p, q e r são cada um independentemente 0, 1, 2 ou 3; n e s são cada um independentemente 1, 2 ou 3; e R¬ a-n¬ e R¬ a<39>-f¬ são cada um independentemente H ou alquila. Aspectos adicionais da invenção refere-sem a composições farmacêuticas que compreendem tais compostos e o seu uso na preparação de um medicamento para o tratamento de um ou mais dos seguintes: um distúrbio proliferativo, um distúrbio viral, um distúrbio do SNC, um derrame, alopecia e diabete.",CYCLACEL LTD,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH W;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE J;;PERRY ALEX;;BLAKE DAVID;;ZHELEVA DANIELLA I;;FISCHER PETER,,https://lens.org/093-553-908-489-875,Patent Application,no,0,0,11,15,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,A61K31/506;;C07D417/04;;C07D417/14,,0,0,,,,DISCONTINUED
62,AU,A1,AU 2004/285745 A1,097-083-093-699-83X,2005-05-12,2005,AU 2004/285745 A,2004-10-21,GB 0330013 A;;GB 0324599 A;;GB 2004004465 W,2003-10-21,"Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy",,CYCLACEL LTD,DUNCAN KENNETH W;;GIBSON DARREN;;BLAKE DAVID;;PERRY ALEX;;MEADES CHRISTOPHER;;WOOD GAVIN;;ZHELEVA DANIELLA I;;FISCHER PETER M;;WANG SHUDONG;;MCLACHLAN JANICE C,,https://lens.org/097-083-093-699-83X,Patent Application,no,0,0,11,15,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,A61K31/506;;C07D417/04;;C07D417/14,,0,0,,,,DISCONTINUED
63,WO,A1,WO 2005/042525 A1,182-878-051-531-940,2005-05-12,2005,GB 2004004465 W,2004-10-21,GB 0324599 A;;GB 0330013 A,2003-10-21,"PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY","The present invention relates to compounds of formula: (I), or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj&rsquo;) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa&rsquo;CORg&rsquo;, Rf&rsquo;, (CH2)rNRb&rsquo;SO2Rh&rsquo;, SO2NRd&rsquo;Ri&rsquo;, SO2NRe&apos;(CH2)s,ORc&apos;, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg&apos;, Rh&apos;, Ri&apos; and Rj&apos; are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3; n and s are each independently 1, 2, or 3; and Ra-n and Ra&apos;-f&apos; are each independently H or alkyl. Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.",CYCLACEL LTD;;WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH W;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE C;;PERRY ALEX;;BLAKE DAVID;;ZHELEVA DANIELLA I;;FISCHER PETER M,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH W;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE C;;PERRY ALEX;;BLAKE DAVID;;ZHELEVA DANIELLA I;;FISCHER PETER M,,https://lens.org/182-878-051-531-940,Patent Application,yes,6,25,11,15,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,A61K31/506;;C07D417/04;;C07D417/14,,0,0,,,,PENDING
64,EP,A1,EP 1678171 A1,186-012-583-965-721,2006-07-12,2006,EP 04768981 A,2004-10-21,GB 2004004465 W;;GB 0324599 A;;GB 0330013 A,2003-10-21,2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,CYCLACEL LTD,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH W;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE C;;PERRY ALEX;;BLAKE DAVID;;ZHELEVA DANIELLA I;;FISCHER PETER M,CYCLACEL LIMITED (2016-01-13),https://lens.org/186-012-583-965-721,Patent Application,yes,0,0,11,15,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,A61K31/506;;C07D417/04;;C07D417/14,,0,0,,,,ACTIVE
65,CA,A1,CA 2542880 A1,099-345-608-663-263,2005-05-12,2005,CA 2542880 A,2004-10-21,GB 0324599 A;;GB 0330013 A;;GB 2004004465 W,2003-10-21,"PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY",,CYCLACEL LTD,ZHELEVA DANIELLA I;;BLAKE DAVID;;PERRY ALEX;;WANG SHUDONG;;GIBSON DARREN;;MEADES CHRISTOPHER;;DUNCAN KENNETH W;;WOOD GAVIN;;MCLACHLAN JANICE C;;FISCHER PETER M,,https://lens.org/099-345-608-663-263,Patent Application,no,0,0,11,15,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/14;;A61K31/506;;C07D417/04,,0,0,,,,DISCONTINUED
66,EP,B1,EP 1678171 B1,127-325-713-712-51X,2016-09-14,2016,EP 04768981 A,2004-10-21,GB 2004004465 W;;GB 0324599 A;;GB 0330013 A,2003-10-21,2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,CYCLACEL LTD,WANG SHUDONG;;WOOD GAVIN;;DUNCAN KENNETH W;;MEADES CHRISTOPHER;;GIBSON DARREN;;MCLACHLAN JANICE C;;PERRY ALEX;;BLAKE DAVID;;ZHELEVA DANIELLA I;;FISCHER PETER M,CYCLACEL LIMITED (2016-01-13),https://lens.org/127-325-713-712-51X,Granted Patent,yes,6,0,11,15,0,C07D417/04;;C07D417/14;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/24;;A61P25/28;;A61P31/10;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D417/04;;C07D417/14,C07D417/14;;A61K31/506;;C07D417/04,,0,0,,,,ACTIVE
67,DE,A1,DE 10354721 A1,077-817-698-196-834,2004-11-11,2004,DE 10354721 A,2003-11-22,DE 10354721 A;;DE 10254837 A,2002-11-25,Disengaging system for a motor vehicle automatic drive has transmission system which self locks a rotating body which is coupled to lock the drive,A disengaging system for at least one coupling of an automatic drive comprises a transmission mechanism (3) which self-locks at least one rotating body which is coupled to lock with both the drive (4) and down drive (5) of the disengaging system. Independent claims are also included for the following: (a) a coupling unit as above; (b) a control process for a motor vehicle automatic drive; and a disengaging system as above.,LUK LAMELLEN & KUPPLUNGSBAU,AHNERT GERD;;SCHNEIDER MATTHIAS;;BUENDER CARSTEN;;REIK WOLFGANG;;FISCHER ROBERT;;BERGER REINHARD;;LINDENSCHMIDT CHRISTOPH;;SPRECKELS MARCUS;;BUCKLER JULIAN ALISTAIR;;KENNEDY IAN DUNCAN;;HARRIES DAVID ANTHONY,"SCHAEFFLER TECHNOLOGIES AG & CO. KG, DE (2015-02-11);;SCHAEFFLER TECHNOLOGIES GMBH & CO. KG, 91074 H, DE (2011-02-10);;SCHAEFFLER TECHNOLOGIES GMBH & CO. KG, DE (2014-02-13)",https://lens.org/077-817-698-196-834,Patent Application,no,0,20,1,1,0,B60W10/02;;B60W10/10;;B60W10/11;;B60W30/18;;B60W30/1819;;F16D29/005;;F16H61/0213;;F16H61/30;;F16H61/32;;F16H61/688;;F16H63/18;;F16H63/46;;F16H2059/003;;F16H2061/0225;;F16H2061/2838,B60W10/02;;B60W10/10;;B60W30/18;;F16D23/12;;F16D29/00;;F16H61/02;;F16H61/30;;F16H61/32;;F16H61/688;;F16H63/18,,0,0,,,,DISCONTINUED
68,MX,A,MX 2013006408 A,178-951-721-196-234,2013-07-15,2013,MX 2013006408 A,2011-12-13,US 201061424300 P;;US 2011/0064525 W,2010-12-17,SYSTEMS AND METHODS FOR RECOVERING HYDROCARBONS FROM A POLYOLEFIN PURGE GAS PRODUCT.,"Provided are systems and methods for separating a purge gas recovered from a polyethylene product. The method includes recovering a polyethylene product containing one or more volatile hydrocarbons from a polymerization reactor and contacting the polyethylene product with a purge gas to remove at least a portion of the volatile hydrocarbons to produce a polymer product having a reduced concentration of volatile hydrocarbons and a purge gas product enriched in volatile hydrocarbons. The purge gas product is compressed to a pressure of 2,500 kPaa to 10,000 kPaa, and is then cooled and separated into at least a first product, a second product, and a third product. A portion of one or more of the first, second, or third products is then recycled as a purge gas, to the polymerization reactor, or to the purge gas product enriched in volatile hydrocarbons prior to compression, respectively.",UNIVATION TECH LLC,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ GEORGE W JR;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER JAMES L;;SMITH CLOID RUSSELL,,https://lens.org/178-951-721-196-234,Patent Application,no,0,0,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,C08F6/00;;B01D53/14;;C07C7/00;;C08J11/02,,0,0,,,,ACTIVE
69,CN,A,CN 103298842 A,193-803-969-225-755,2013-09-11,2013,CN 201180065173 A,2011-12-13,US 2011/0064525 W;;US 201061424300 P,2010-12-17,Systems and methods for recovering hydrocarbons from a polyolefin purge gas product,"Provided are systems and methods for separating a purge gas recovered from a polyethylene product. The method includes recovering a polyethylene product containing one or more volatile hydrocarbons from a polymerization reactor and contacting the polyethylene product with a purge gas to remove at least a portion of the volatile hydrocarbons to produce a polymer product having a reduced concentration of volatile hydrocarbons and a purge gas product enriched in volatile hydrocarbons. The purge gas product is compressed to a pressure of 2,500 kPaa to 10,000 kPaa, and is then cooled and separated into at least a first product, a second product, and a third product. A portion of one or more of the first, second, or third products is then recycled as a purge gas, to the polymerization reactor, or to the purge gas product enriched in volatile hydrocarbons prior to compression, respectively.",UNIVATION TECH LLC,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER JAMES L;;SMITH CLOID RUSSELL,,https://lens.org/193-803-969-225-755,Patent Application,no,3,11,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,C08F6/00;;B01D53/14;;C07C7/00;;C08J11/02,,0,0,,,,ACTIVE
70,WO,A1,WO 2012/082674 A1,103-622-849-469-643,2012-06-21,2012,US 2011/0064525 W,2011-12-13,US 201061424300 P,2010-12-17,SYSTEMS AND METHODS FOR RECOVERING HYDROCARBONS FROM A POLYOLEFIN PURGE GAS PRODUCT,"Provided are systems and methods for separating a purge gas recovered from a polyethylene product. The method includes recovering a polyethylene product containing one or more volatile hydrocarbons from a polymerization reactor and contacting the polyethylene product with a purge gas to remove at least a portion of the volatile hydrocarbons to produce a polymer product having a reduced concentration of volatile hydrocarbons and a purge gas product enriched in volatile hydrocarbons. The purge gas product is compressed to a pressure of 2,500 kPaa to 10,000 kPaa, and is then cooled and separated into at least a first product, a second product, and a third product. A portion of one or more of the first, second, or third products is then recycled as a purge gas, to the polymerization reactor, or to the purge gas product enriched in volatile hydrocarbons prior to compression, respectively.",UNIVATION TECH LLC;;BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER JAMES L;;SMITH CLOID RUSSELL,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER JAMES L;;SMITH CLOID RUSSELL,,https://lens.org/103-622-849-469-643,Patent Application,yes,138,10,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,C08F6/00;;B01D53/14;;C07C7/00;;C08J11/02,,0,0,,,,PENDING
71,KR,A,KR 20130140111 A,176-517-369-565-736,2013-12-23,2013,KR 20137018569 A,2011-12-13,US 201061424300 P;;US 2011/0064525 W,2010-12-17,SYSTEMS AND METHODS FOR RECOVERING HYDROCARBONS FROM A POLYOLEFIN PURGE GAS PRODUCT,,UNIVATION TECH LLC,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER JAMES L;;SMITH CLOID RUSSELL,,https://lens.org/176-517-369-565-736,Patent Application,no,0,2,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,B01D53/14;;C07C7/00;;C08F6/10;;C08J11/02,,0,0,,,,ACTIVE
72,MX,B,MX 337727 B,078-922-211-135-580,2016-03-16,2016,MX 2013006408 A,2011-12-13,US 201061424300 P;;US 2011/0064525 W,2010-12-17,SYSTEMS AND METHODS FOR RECOVERING HYDROCARBONS FROM A POLYOLEFIN PURGE GAS PRODUCT.,"Provided are systems and methods for separating a purge gas recovered from a polyethylene product. The method includes recovering a polyethylene product containing one or more volatile hydrocarbons from a polymerization reactor and contacting the polyethylene product with a purge gas to remove at least a portion of the volatile hydrocarbons to produce a polymer product having a reduced concentration of volatile hydrocarbons and a purge gas product enriched in volatile hydrocarbons. The purge gas product is compressed to a pressure of 2,500 kPaa to 10,000 kPaa, and is then cooled and separated into at least a first product, a second product, and a third product. A portion of one or more of the first, second, or third products is then recycled as a purge gas, to the polymerization reactor, or to the purge gas product enriched in volatile hydrocarbons prior to compression, respectively.",UNIVATION TECH LLC,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ GEORGE W JR;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER JAMES L;;SMITH CLOID RUSSELL,,https://lens.org/078-922-211-135-580,Granted Patent,no,0,0,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,C08F6/00;;B01D53/14;;C07C7/00;;C08J11/02,,0,0,,,,ACTIVE
73,EP,B1,EP 2651982 B1,123-930-969-746-721,2018-04-11,2018,EP 11806052 A,2011-12-13,US 201061424300 P;;US 2011/0064525 W,2010-12-17,SYSTEMS AND METHODS FOR RECOVERING HYDROCARBONS FROM A POLYOLEFIN PURGE GAS PRODUCT,,UNIVATION TECH LLC,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER JAMES L;;SMITH CLOID RUSSELL,,https://lens.org/123-930-969-746-721,Granted Patent,yes,3,2,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,C08F6/00;;B01D53/00;;B01D53/14;;C07C7/00;;C08J11/02;;C08L23/00;;F25J3/06;;F25J3/08,,0,0,,,,ACTIVE
74,EP,A1,EP 2651982 A1,109-799-108-028-172,2013-10-23,2013,EP 11806052 A,2011-12-13,US 201061424300 P;;US 2011/0064525 W,2010-12-17,SYSTEMS AND METHODS FOR RECOVERING HYDROCARBONS FROM A POLYOLEFIN PURGE GAS PRODUCT,,UNIVATION TECH LLC,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER JAMES L;;SMITH CLOID RUSSELL,,https://lens.org/109-799-108-028-172,Patent Application,yes,0,0,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,C08F6/00;;B01D53/14;;C07C7/00;;C08J11/02,,0,0,,,,ACTIVE
75,BR,B1,BR 112013014992 B1,162-521-425-831-941,2020-12-29,2020,BR 112013014992 A,2011-12-13,US 2011/0064525 W;;US 201061424300 P,2010-12-17,sistemas e métodos para recuperar hidrocarbonetos de um produto gasoso da purga de poliolefina,"sistema e método para recuperar hidrocarbonetos de um produto gasoso da purga de poliolefina. a presente invenção refere-se a sistema e a métodos para separar um gás de purga recuperado de um produto de polietileno. o método pode incluir a recuperação de um produto de polietileno contendo um ou mais hidrocarbonetos voláteis de um reator de polimerização e contato do produto de polietileno com um gás de purga para remover pelo menos uma porção dos hidrocarbonetos voláteis para produzir um produto polimérico tendo uma concentração reduzida de hidrocarbonetos voláteis e um produto gasoso da purga enriquecido em hidrocarbonetos voláteis. o produto gasoso de purga pode ser comprimido a uma pressão de aproximadamente 2.500 kpaa a aproximadamente 10.000 kpaa, e então pode ser resfriado e separado em pelo menos um primeiro produto, um segundo produto e um terceiro produto. uma porção de um ou mais dentre o primeiro, o segundo ou o terceiro produtos então pode ser reciclada como um gás de purga, no reator de polimerização, ou no produto gasosos de purga enriquecido em hidrocarbonetos voláteis antes da compressão, respectivamente.",UNIVATION TECH LLC,CLOID RUSSELL SMITH;;DANIEL W MOSSER;;DONALD A FISCHER;;GEORGE W SCHWARZ JR;;JAMES L SWECKER;;MARK W BLOOD;;RANDALL L FORCE;;ROBERT D OLSON;;THEODORE D DUNCAN,,https://lens.org/162-521-425-831-941,Granted Patent,no,0,0,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,B01D53/14;;C07C7/00;;C08F6/00;;C08J11/02,,0,0,,,,ACTIVE
76,BR,A2,BR 112013014992 A2,083-959-938-646-285,2018-05-15,2018,BR 112013014992 A,2011-12-13,US 2011/0064525 W;;US 201061424300 P,2010-12-17,sistemas e métodos para recuperar hidrocarbonetos de um produto gasoso da purga de poliolefina,,UNIVATION TECH LLC,CLOID RUSSELL SMITH;;DANIEL W MOSSER;;DONALD A FISCHER;;GEORGE W SCHWARZ JR;;JAMES L SWECKER;;MARK W BLOOD;;RANDALL L FORCE;;ROBERT D OLSON;;THEODORE D DUNCAN,,https://lens.org/083-959-938-646-285,Patent Application,no,0,0,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,B01D53/14;;C07C7/00;;C08F6/00;;C08J11/02,,0,0,,,,ACTIVE
77,DE,A1,DE 10312397 A1,166-844-695-089-953,2003-11-06,2003,DE 10312397 A,2003-03-20,DE 10312397 A;;DE 10212544 A,2002-03-21,Method of determining reference geometry for motor vehicle automatic gearbox involves determining actual neutral path geometry in comparison to preset value,"The method of determining reference geometry for a motor vehicle automatic transmission involves comparing the gearbox geometry for at least one value corresponding to the gearbox geometry, with a non-plausible value replaced by a preset value. The value of geometry used can include the actual length of the neutral path which is compared to a set value. claims include a gearbox actuator using the method.",LUK LAMELLEN & KUPPLUNGSBAU,BAST FRANK;;EICH JUERGEN;;FISCHER ROBERT;;HENNEBERGER KLAUS;;KENNEDY IAN DUNCAN;;KNEISSLER MARKUS;;KUEPPER KLAUS;;MAXON ANDREAS;;MOOSHEIMER JOHANNES;;SCHNEIDER GEORG;;SEREBRENNIKOV BORIS;;STENGEL FRANK;;VORNEHM MARTIN;;ZIMMERMANN MARTIN,"SCHAEFFLER TECHNOLOGIES AG & CO. KG, DE (2015-02-11);;SCHAEFFLER TECHNOLOGIES GMBH & CO. KG, 91074 H, DE (2011-02-10);;SCHAEFFLER TECHNOLOGIES GMBH & CO. KG, DE (2014-02-17)",https://lens.org/166-844-695-089-953,Patent Application,no,0,6,4,24,0,F16H61/28;;F16H61/12;;F16H61/32;;F16H2059/006;;F16H2061/0087;;F16H2061/1208;;F16H2061/2823;;F16H2061/283;;F16H2342/02,F16H61/00;;F16H61/02;;F16H61/12;;F16H61/28;;F16H61/32,,0,0,,,,DISCONTINUED
78,US,A1,US 2013/0291720 A1,093-605-233-166-649,2013-11-07,2013,US 201113992465 A,2011-12-13,US 201113992465 A;;US 201061424300 P;;US 2011/0064525 W,2010-12-17,Systems and Methods for Recovering Hydrocarbons From a Polyolefin Purge Gas Product,"Provided are systems and methods for separating a purge gas recovered from a polyethylene product. The method includes recovering a polyethylene product containing one or more volatile hydrocarbons from a polymerization reactor and contacting the polyethylene product with a purge gas to remove at least a portion of the volatile hydrocarbons to produce a polymer product having a reduced concentration of volatile hydrocarbons and a purge gas product enriched in volatile hydrocarbons. The purge gas product is compressed to a pressure of 2,500 kPaa to 10,000 kPaa, and is then cooled and separated into at least a first product, a second product, and a third product. A portion of one or more of the first, second, or third products is then recycled as a purge gas, to the polymerization reactor, or to the purge gas product enriched in volatile hydrocarbons prior to compression, respectively.",BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER II JAMES LELAND;;SMITH III CLOID RUSSELL;;UNIVATION TECH LLC,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER II JAMES LELAND;;SMITH III CLOID RUSSELL,,https://lens.org/093-605-233-166-649,Patent Application,yes,2,35,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,F25J3/08;;C08F6/00,95/39;;62/618,0,0,,,,ACTIVE
79,US,B2,US 9181361 B2,149-521-354-478-86X,2015-11-10,2015,US 201113992465 A,2011-12-13,US 201113992465 A;;US 201061424300 P;;US 2011/0064525 W,2010-12-17,Systems and methods for recovering hydrocarbons from a polyolefin purge gas product,"Provided are systems and methods for separating a purge gas recovered from a polyethylene product. The method includes recovering a polyethylene product containing one or more volatile hydrocarbons from a polymerization reactor and contacting the polyethylene product with a purge gas to remove at least a portion of the volatile hydrocarbons to produce a polymer product having a reduced concentration of volatile hydrocarbons and a purge gas product enriched in volatile hydrocarbons. The purge gas product is compressed to a pressure of 2,500 kPaa to 10,000 kPaa, and is then cooled and separated into at least a first product, a second product, and a third product. A portion of one or more of the first, second, or third products is then recycled as a purge gas, to the polymerization reactor, or to the purge gas product enriched in volatile hydrocarbons prior to compression, respectively.",BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER II JAMES LELAND;;SMITH III CLOID RUSSELL;;UNIVATION TECH LLC,BLOOD MARK W;;FORCE RANDALL L;;DUNCAN THEODORE D;;SCHWARZ JR GEORGE W;;MOSSER DANIEL W;;FISCHER DONALD A;;OLSON ROBERT D;;SWECKER II JAMES LELAND;;SMITH III CLOID RUSSELL,,https://lens.org/149-521-354-478-86X,Granted Patent,yes,11,0,17,17,0,B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/00;;C08F6/00;;C08F6/005;;C08F6/00;;C08F6/10;;C07C7/00;;C08J11/02;;B01D53/14;;B01D53/00;;C08F6/00;;B01D53/002;;B01D2256/10;;B01D2256/24;;B01D2257/102;;B01D2257/702;;B01D2257/708;;B01J2219/00006;;F25J3/062;;F25J3/064;;F25J3/066;;F25J2210/12;;F25J2220/02;;F25J2230/30;;F25J2235/60;;F25J2260/42;;F25J2260/60;;B01D53/1487;;C07C7/005;;C08F6/005;;C08J11/02;;F25J3/08,B01D53/00;;B01D53/14;;C07C7/00;;C08F6/00;;C08J11/02;;F25J3/06;;F25J3/08,,1,0,,,"Japanese Notice of Reasons of Refusal for related JP Patent Application No. 2013-544663, filed Jun. 14, 2013, mailed on May 19, 2015 (4 pgs).",ACTIVE
